However, this list is not exhaustive, and other conditions, such as impaired splenic function, may also warrant additional vaccine doses. Refer to other UpToDate content for details.
¶ For children 6 months through 4 years old and for individuals with a moderate to severe immunocompromising condition, an initial vaccination series includes 2 or 3 doses of a COVID-19 vaccine, depending on which vaccine is used. Refer to other UpToDate content for details. For those who have not previously completed an initial vaccination series, a 2024-2025 Formula vaccine should be used to complete the series.
Δ If a 2024-2025 Formula vaccine was used as part of the initial series, that can count towards this dose. If not, this 2024-2025 Formula vaccine dose should be given at least 2 months after the previous COVID-19 vaccine dose.
◊ For those who have previously received a COVID-19 vaccine dose, this 2024-2025 Formula vaccine dose should be given at least 2 months later. For those who are previously unvaccinated and receiving a Novavax 2024-2025 Formula vaccine, 2 vaccine doses are given, 3 to 8 weeks apart.
§ The clinical effect of multiple 2024-2025 Formula vaccines is uncertain, and data are limited. We are more likely to suggest additional vaccination for individuals with expected high risk of exposure and profound immunosuppression.